Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Zanubrutinib

FDA-approved product (capsule, oral), marketed as Brukinsa.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Zanubrutinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Mantle cell lymphoma
  • Neoplasm
  • Waldenstrom macroglobulinemia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Bruton's tyrosine kinase (btk) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis51.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Zanubrutinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-10.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Zanubrutinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Epco, Zanu, Ritux for R/R FL or MZL

    NCT06563596 · start 2025-01-21

    Registered record
    Registry ID
    NCT06563596
    Conditions
    Follicular Lymphoma; Lymphoma; Non-Hodgkin Lymphoma; Relapsed Lymphoma; Refractory Lymphoma; Marginal Zone Lymphoma
    Interventions
    Zanubrutinib; Rituximab; Epcoritamab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-01-21
    Completion
    2030-03-01
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFollicular Lymphoma; Lymphoma; Non-Hodgkin Lymphoma; Relapsed Lymphoma +2 more
    InterventionZanubrutinib; Rituximab; Epcoritamab
    PhasePhase 2
    Registry statusRecruiting

  • Study to Assess Effectiveness and Safety of Zanubrutinib for Patients With Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)

    NCT06823960 · start 2024-12-09

    Registered record
    Registry ID
    NCT06823960
    Conditions
    Marginal Zone Lymphoma(MZL)
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-12-09
    Completion
    2025-06
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMarginal Zone Lymphoma(MZL)
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)

    NCT06647732 · start 2024-10-30

    Registered record
    Registry ID
    NCT06647732
    Conditions
    Mucosa-associated Lymphoid Tissue Lymphoma (MALT)
    Interventions
    Zanubrutinib; Rituximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2024-10-30
    Completion
    2028-09-30
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMucosa-associated Lymphoid Tissue Lymphoma (MALT)
    InterventionZanubrutinib; Rituximab
    PhasePhase 2
    Registry statusActive not recruiting

  • Pola-ZR2P in Previously Untreated DLBCL

    NCT06664411 · start 2024-09-24

    Registered record
    Registry ID
    NCT06664411
    Conditions
    Diffuse Large B-cell Lymphoma
    Interventions
    Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone as Induction Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-09-24
    Completion
    2030-12
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiffuse Large B-cell Lymphoma
    InterventionPolatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone as Induction Therapy
    PhasePhase 2
    Registry statusRecruiting

  • Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    NCT06544785 · start 2024-09-02

    Registered record
    Registry ID
    NCT06544785
    Conditions
    Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    Interventions
    Zanubrutinib Oral Product; Obinutuzumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-09-02
    Completion
    2032-05-31
    Enrolment
    106

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    InterventionZanubrutinib Oral Product; Obinutuzumab
    PhasePhase 2
    Registry statusRecruiting

  • Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma

    NCT06471738 · start 2024-07-10

    Registered record
    Registry ID
    NCT06471738
    Conditions
    Ann Arbor Stage II Follicular Lymphoma; Grade 1 Follicular Lymphoma; Ann Arbor Stage III Follicular Lymphoma; Ann Arbor Stage IV Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3a Follicular Lymphoma
    Interventions
    Zanubrutinib; Rituximab; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-07-10
    Completion
    2027-06-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnn Arbor Stage II Follicular Lymphoma; Grade 1 Follicular Lymphoma; Ann Arbor Stage III Follicular Lymphoma; Ann Arbor Stage IV Follicular Lymphoma +2 more
    InterventionZanubrutinib; Rituximab; Venetoclax
    PhasePhase 2
    Registry statusRecruiting

  • This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma

    NCT06427213 · start 2024-05-20

    Registered record
    Registry ID
    NCT06427213
    Conditions
    Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin
    Interventions
    Zanubrutinib,Obinutuzumab; Zanubrutinib and R-BAC
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2024-05-20
    Completion
    2029-12-30
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin
    InterventionZanubrutinib,Obinutuzumab; Zanubrutinib and R-BAC
    PhasePhase 2
    Registry statusNot yet recruiting

  • Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

    NCT06350318 · start 2024-04-19

    Registered record
    Registry ID
    NCT06350318
    Conditions
    Follicular Lymphoma; Marginal Zone Lymphoma; B-Cell Lymphoma
    Interventions
    Zanubrutinib; Rituximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-04-19
    Completion
    2029-03
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFollicular Lymphoma; Marginal Zone Lymphoma; B-Cell Lymphoma
    InterventionZanubrutinib; Rituximab
    PhasePhase 2
    Registry statusRecruiting

  • Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma

    NCT06553352 · start 2024-03-31

    Registered record
    Registry ID
    NCT06553352
    Conditions
    Follicular Lymphoma; Newly Diagnosed
    Interventions
    Zanubrutinib combined with Obinutuzumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-03-31
    Completion
    2027-08-31
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFollicular Lymphoma; Newly Diagnosed
    InterventionZanubrutinib combined with Obinutuzumab
    PhasePhase 2
    Registry statusRecruiting

  • A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL

    NCT06375733 · start 2024-03-20

    Registered record
    Registry ID
    NCT06375733
    Conditions
    Large B-cell Lymphoma
    Interventions
    GFH009; Zanubrutinib; GFH009; Zanubrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2024-03-20
    Completion
    2026-12-31
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLarge B-cell Lymphoma
    InterventionGFH009; Zanubrutinib; GFH009; Zanubrutinib
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

    NCT06547944 · start 2024-01-01

    Registered record
    Registry ID
    NCT06547944
    Conditions
    Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Newly Diagnosed
    Interventions
    Zanubrutinib; Lenalidomide; Obinutuzumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2024-01-01
    Completion
    2026-12-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Newly Diagnosed
    InterventionZanubrutinib; Lenalidomide; Obinutuzumab
    PhasePhase 1
    Registry statusActive not recruiting

  • Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase Inhibitors

    NCT05495828 · start 2023-11-10

    Registered record
    Registry ID
    NCT05495828
    Conditions
    B-cell Lymphoma
    Interventions
    Orelabrutinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2023-11-10
    Completion
    2025-03-10
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionB-cell Lymphoma
    InterventionOrelabrutinib
    PhaseNot recorded
    Registry statusUnknown

  • Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL

    NCT06033820 · start 2023-10-12

    Registered record
    Registry ID
    NCT06033820
    Conditions
    Diffuse Large B-cell Lymphoma Recurrent; Diffuse Large B Cell Lymphoma Refractory
    Interventions
    ZR2-ICE
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2023-10-12
    Completion
    2025-06-30
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiffuse Large B-cell Lymphoma Recurrent; Diffuse Large B Cell Lymphoma Refractory
    InterventionZR2-ICE
    PhasePhase 2
    Registry statusUnknown

  • Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

    NCT05890352 · start 2023-09-26

    Registered record
    Registry ID
    NCT05890352
    Conditions
    Grade 3b Follicular Lymphoma; High Grade B-Cell Lymphoma; High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements; Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Transformed Non-Hodgkin Lymphoma
    Interventions
    Biospecimen Collection; Computed Tomography; Lenalidomide; Magnetic Resonance Imaging; Positron Emission Tomography; Quality-of-Life Assessment; Questionnaire Administration; Tafasitamab; Tazemetostat; Zanubrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-09-26
    Completion
    2029-01
    Enrolment
    227

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGrade 3b Follicular Lymphoma; High Grade B-Cell Lymphoma; High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements; Recurrent Diffuse Large B-Cell Lymphoma +2 more
    InterventionBiospecimen Collection; Computed Tomography; Lenalidomide; Magnetic Resonance Imaging +6 more
    PhasePhase 2
    Registry statusRecruiting

  • The Safety and Efficacy of Zanubrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia

    NCT06021977 · start 2023-09-01

    Registered record
    Registry ID
    NCT06021977
    Conditions
    Refractory/Relapsed Autoimmune Hemolytic Anemia
    Interventions
    Zanubrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2023-09-01
    Completion
    2025-12-31
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRefractory/Relapsed Autoimmune Hemolytic Anemia
    InterventionZanubrutinib
    PhasePhase 2
    Registry statusUnknown